News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Shkreli Called it: Mast Therapeutics (MSTX) Begins Winding Down Vepoloxamer Programs 9/26/2016
Axovant (AXON) Receives FDA Fast-Track Designation For Intepirdine As An Investigational Treatment For Dementia With Lewy Bodies 9/26/2016
Achillion (ACHN) Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen’s Phase II Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naïve HCV 9/26/2016
Lipocine (LPCN) Announces Positive Top-Line Phase IIb Study Results For LPCN 1111, A Next Generation Oral Testosterone Replacement Therapy 9/26/2016
Galapagos (GLPG.BR) Release: Endoscopic Improvements With Filgotinib Are Consistent With Clinical Remission Rates In Patients With Crohn's Disease 9/26/2016
Summit Therapeutics Receives FDA Fast Track Status for DMD Treatment 9/26/2016
Alnylam (ALNY) Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational Rnai Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 9/26/2016
Medivir (MVRBF): Updated Interim Phase IIa Data Demonstrate That The Combination Of Simeprevir, Odalasvir And AL-335 Has A High Level Of Efficacy In HCV Patients 9/26/2016
AbbVie (ABBV) Announces Submission Of A Supplemental New Drug Application For Ibrutinib (IMBRUVICA) For Treatment Of Marginal Zone Lymphoma 9/26/2016
ERYtech Pharma Completes Patient Enrollment In Phase 2 Trial Of Eryaspase (GRASPA) For Pancreatic Cancer 9/26/2016
Abeona Therapeutics Enrolls First Patient In Phase 2 For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa 9/26/2016
Cytori (CYTX) Partner Kerastem Completes Enrollment Of U.S. Phase II Trial For Early Stage Hair Loss 9/26/2016
SciClone (SCLN) Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market 9/26/2016
Investors Beware: Thin CAR-T Data Could Make or Break Juno (JUNO) and Kite Pharma (KITE) 9/23/2016
Gilead (GILD) Terminates Phase II/III Study of Ulcerative Colitis Drug 9/23/2016
Fundación MAPFRE Presents The Results Of Personalized Cell Therapy For Treating Spinal Cord Injury 9/23/2016
Entasis Announces Positive Phase 2 Data Of ETX0914 For The Treatment Of Gonorrhea 9/23/2016
Nordic Nanovector: Safety Review Committee Supports Dose Escalation With Betalutin In Lymrit 37-01 Trial Pending Safety Data From Cohort Receiving Higher Pre-Dosing 9/23/2016
Kerastem Completes Enrollment in US Phase II Hair Growth Clinical Trial 9/23/2016
Medivir (MVRBF): MIV-711 Osteoarthritis Trial: Recommendation To Go Ahead Based On Independent Review Of Safety Data, And First Patient Enrolled In Extension Study 9/23/2016
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 In Psoriasis 9/23/2016
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 In Chronic Graft-Versus Host Disease 9/23/2016
Entasis Announces Positive Phase 2 Data Of ETX0914 For The Treatment Of Gonorrhea 9/22/2016
Neuraltus Pharmaceuticals, Inc. Initiates Confirmatory Phase 2 Study Of NP001 In Patients With Amyotrophic Lateral Sclerosis 9/22/2016
ASIT Biotech Announces The Initiation Of A Phase IIa Clinical Study Of Its Second Product Candidate Hdm-ASIT+TM For House Dust Mite Rhinitis 9/22/2016
Syros Pharma Announces First Patient Enrolled In Phase II Clinical Trial Of SY-1425 In Genomically Defined Patients With Acute Myeloid Leukemia Or Myelodysplastic Syndrome 9/22/2016
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 In Psoriasis 9/22/2016
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 In Chronic Graft-Versus Host Disease 9/22/2016
Bionomics Limited (BNO.AX) Announces Positive Results From Phase 2 Trial Of BNC210 In Generalized Anxiety Disorder 9/21/2016
Actinium (ATNM.OB) To Host Webinar To Provide Update On Actimab-A Phase II Clinical Trial 9/21/2016
bluebird bio (BLUE) Release: Lentiglobin Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into EMA’s PRIME Program 9/21/2016
DBV Tech Receives FDA Fast Track Designation For Viaskin Milk For The Treatment Of Cow’s Milk Protein Allergy 9/21/2016
SanBio, Inc. Begins Clinical Trial Of Regenerative Cell Medicine For Patients With Traumatic Brain Injury In Japan 9/21/2016
BiondVax Pharmaceuticals Phase 2b European Trial: Last Patient Out 9/21/2016
Cerecor Inc. Announces Completion Of Enrollment In Phase II Clinical Trial With CERC-301 As An Oral, Adjunctive Treatment Of Major Depressive Disorder 9/21/2016
Cidara (CDTX) Selects First Development Candidate From Its Cloudbreak Immunotherapy Discovery Platform 9/21/2016
Tyme Announces William K. Oh, M.D., Chief Of The Division Of Hematology And Medical Oncology At Mount Sinai, As Special Advisor For A Phase II Trial For Recurrent Prostate Cancer Patients Being Planned At Mount Sinai Hospital 9/20/2016
Sunovion Announces Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD 9/20/2016
Synthetic Biologics (SYN) Announces Completion Of Enrollment For Phase 2b Proof-Of-Concept Clinical Trial For SYN-004 (Ribaxamase) For The Prevention Of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea And The Emergence Of Antibiotic-Resistant Organisms 9/20/2016
Windtree Therapeutics (WINT) Announces FDA Fast Track Designation For AEROSURF 9/20/2016
BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 9/20/2016
Novartis AG (NVS) Says Experimental Drug Helps Chronic Migraine Sufferers 9/19/2016
Stealth Biotherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics In The Elderly 9/19/2016
Cytokinetics (CYTK) Announces Presentation Of Additional Results From COSMIC-HF At The HFSA Annual Scientific Meeting 9/19/2016
Catalyst Pharma (CPRX) Announces Publication Of CPP-115 Clinical Efficacy Data For Infantile Spasms In Epilepsy & Behavior Case Reports 9/19/2016
NeuroDerm (NDRM) To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System 9/19/2016
Astellas (ALPMY), Vical  (VICL)'s Experimental Herpes Vaccine Flunks Mid-Stage Test 9/19/2016
NovaBay (NBY)’ Auriclosene Demonstrates Statistically Significant And Clinically Meaningful Results In Phase 2b Study For The Prevention Of Urinary Catheter Blockage And Encrustation 9/19/2016
Teva (TEVA) Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study Of Pridopidine In Huntington Disease 9/19/2016
Akebia (AKBA) Announces Publication Of Phase IIb Data For Vadadustat In Non-Dialysis Patients With Anemia Related To Chronic Kidney Disease 9/19/2016
Enteris Biopharma's "Feasibility To Licensing" Partner, Cara Therapeutics (CARA), Advances Peptelligence-Engineered CR845 Into Phase 2b Clinical Trial In Chronic Pain 9/19/2016
Quark Pharmaceuticals Inc. Chief Scientist Provides An Overview Of The Company's Clinical And Nonclinical Pipelines 9/19/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year 9/16/2016
Interim Results From Trek Therapeutics' Phase 2 Study Show Triple Combination Therapy Achieves 100% SVR4 In Genotype 4 HCV Patients 9/16/2016
Amgen (AMGN) Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine 9/16/2016
Celgene (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase 2 Radiance Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
Celgene International Sárl (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase II RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
BioTime (BTX) Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial In Patients With Complete Cervical Spinal Cord Injuries 9/16/2016
Retrotope Announces Phase I/II Clinical Trial Results Of RT001 In Treatment Of Friedreich’s Ataxia 9/16/2016
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 9/15/2016
Poxel SAS Presents New Data On Imeglimin And PXL770 At The European Association For The Study Of Diabetes Annual Meeting 9/15/2016
Cumberland Pharmaceuticals (CPIX) Announces New Program To Develop Portaban For Portal Hypertension 9/15/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease 9/15/2016
Eisai Company (ESALY.PK) Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 9/15/2016
Azevan Pharmaceuticals Reports Positive Phase 2 Exploratory Clinical Study Results With SRX246 In Intermittent Explosive Disorder 9/14/2016
Asterias Biotherapeutics AST-OPC1 Treatment For Spinal Cord Injury Patients Shown To Help Patients Paralyzed From The Neck Down Regain Function In The Arms And Hands 9/14/2016
Inhibikase Therapeutics Receives FDA Clearance To Initiate Clinical Trials For Potential Disease-Modifying Therapies To Treat Parkinson's Disease 9/14/2016
Euroscreen S.A. Completes Enrollment In Phase II Trial Of Lead Candidate ESN364 In Menopausal Hot Flashes 9/14/2016
Despite Trial Deaths, Juno (JUNO) Could Still Be the CAR-T Leader 9/13/2016
UPDATE - RespireRx (RSRX) Announces Preliminary Top-Line Analysis Of Data From Duke University Phase 2A Clinical Trial Of CX1739 9/13/2016
10 Biotechs—Count ‘Em, 10!—With Big Decisions in the Fourth Quarter 9/13/2016
Struggling AVEO Oncology (AVEO) Quietly Discontinues Phase II Ficlatuzumab Study 9/13/2016
FDA Allows Ablative Solutions To Initiate Its Phase 2 TARGET-BP I Trial Of Combination Drug/Device Therapy For Hypertension Under Its IND 9/13/2016
Aptinyx Receives FDA Fast Track Designation For Development Of NYX-2925 As Treatment For Neuropathic Pain Associated With Diabetic Peripheral Neuropathy 9/13/2016
Ligand (LGND) Initiates Phase II Trial With LGD-6972 In Type 2 Diabetes 9/13/2016
Flex Pharma (FLKS) Initiates Phase 2 Efficacy Study In Amyotrophic Lateral Sclerosis 9/13/2016
Foamix Pharma (FOMX) Announces Positive Topline Results From Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam For Moderate-To-Severe Papulopustular Rosacea 9/12/2016
Gilead (GILD) Looks Over Shoulder as Johnson & Johnson (JNJ) Eyes Taking a Bite Out of Hep C Market 9/12/2016
Geron (GERN) Stock Drops on Imetelstat Update, Trials are Continuing 9/12/2016
RespireRx (RSRX) Announces Preliminary Top-Line Analysis Of Data From Duke University Phase 2A Clinical Trial Of CX1739 9/12/2016
Stealth Biotherapeutics Initiates Phase 2 Study Of Elamipretide In Primary Mitochondrial Disease 9/12/2016
MGB Biopharma Limited Granted Qualified Infectious Disease Product (QIPD) Designation By U.S. FDA For The Treatment Of Clostridium Difficile-Associated Diarrhoea (CDAD) For MGB-BP-3 9/12/2016
Soligenix (SNGX) And SciClone (SCLN) Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis 9/12/2016
Achillion (ACHN), Johnson & Johnson (JNJ)'s Hep C Candidate Scores a 100% Cure Rate in Phase IIa Trial 9/9/2016
Medivir (MVRBF): Interim Results From Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level Of Efficacy In HCV Patients 9/9/2016
Foamix Pharma (FOMX) To Announce Topline Results In Phase 2 Clinical Trial Of FMX-103 Minocycline Topical Foam For Moderate-To-Severe Papulopustular Rosacea 9/9/2016
BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference 9/8/2016
Repros Therapeutics (RPRX) Provides Phase II Results Showing Positive Outcomes For Oral Proellex In Women With Moderate To Severe Endometriosis 9/8/2016
Heron (HRTX) Announces Presentations Of Results From Phase II Clinical Trial Of HTX-011 In Hernia Repair At PainWeek 2016 9/8/2016
Biogen (BIIB) Demonstrates Commitment To Improving Patient Outcomes With Study On Burden Of MS And New Clinical Data From Its Leading MS Portfolio 9/8/2016
GTx, Inc. (GTXI) Achieves Stage 1 Milestone In Phase II Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer 9/8/2016
Ovid Receives Orphan Drug Designation From The FDA For OV101 For The Treatment Of Patients With Angelman Syndrome 9/8/2016
ErgoMed Completes Recruitment Of Phase lla Clinical Trial Of Lorediplon In Insomnia In Collaboration With Co-Development Partner Ferrer 9/8/2016
Allakos Initiates Phase 2 Trial Of AK001 In Patients With Nasal Polyposis 9/8/2016
RedHill Biopharma (RDHL) Announces Phase Ib/II Study With YELIVA Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center 9/8/2016
Cytokinetics (CYTK) Announces Next-Generation Fast Skeletal Muscle Activator Entering IND-Enabling Studies 9/8/2016
Cancer Drug Developed by Eliza Hall Institute, AbbVie (ABBV) and Genentech (RHHBY) “Melts Away Cancer” 9/7/2016
Patara Pharma Announces Positive Phase 2 Results For The Treatment Of Refractory Chronic Cough In Patients With Idiopathic Pulmonary Fibrosis 9/7/2016
Retrophin (RTRX) Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis 9/7/2016
Leading Biosciences Receives FDA Clearance To Proceed With Phase 2 Clinical Trial Of LB1148 For Ileus And Adhesions 9/7/2016
Eiger Biopharma Announces Completion Of Dosing In Phase 2 LOWR HDV - 4 Study At Hannover Medical School 9/7/2016
CytRx (CYTR) Announces The Completion Of Enrollment In Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Patients With Second-Line Small Cell Lung Cancer 9/7/2016
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP And Fast Track Designations For Prophylaxis Of Invasive Fungal Infections By U.S. FDA 9/7/2016
Ligand (LGND) Partner Retrophin (RTRX) Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis 9/7/2016
Capricor Therapeutics, Inc. Completes Enrollment In Randomized HOPE Clinical Trial In Duchenne Muscular Dystrophy 9/7/2016
Spherix (SPEX) Awarded Phase II National Science Foundation SBIR Grant To Support Commercialization Of Total Holographic Characterization 9/7/2016
September is a Busy Month for 7 Biotechs 9/6/2016
Karyopharm (KPTI) Touts Mid-Stage Data, May See Quicker Approval of Multiple Myeloma Drug 9/6/2016
SAGE Therapeutics (SAGE) Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression 9/6/2016
Arsanis Announces Two Key Publications Supporting Its Lead Program ASN100 9/6/2016
Catalyst Pharma (CPRX) Announces FDA Orphan Drug Designation Of Firdapse For The Treatment Of Myasthenia Gravis 9/6/2016
Zynerba (ZYNE) Launches Phase II Clinical Trial Of ZYN002 CBD Gel For Treatment Of Osteoarthritis 9/6/2016
Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99mrhannexin V-128 Imaging In Cardiovascular And Cardio-Oncology Indications At University of Ottawa Heart Institute And Ottawa Hospital 9/6/2016
Cerecor Inc. Announces Last Patient Enrolled In Phase II Clinical Trial With CERC-501 For Smoking Cessation 9/6/2016
Arrowhead Pharma (ARWR) Initiates Phase II Study Of ARC-AAT 9/6/2016
Santalis Initiates A Phase II Study Of Mild, Moderate And Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site 9/6/2016
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016
Galapagos (GLPG.BR) Release: Orphan Drug Designation In European Union For GLPG1690 In Idiopathic Pulmonary Fibrosis 9/6/2016
Nordic Nanovector: Lilotomab Pre-Dosing Of NHL Patients Before Betalutin Therapy Lowers Hematological Toxicity With No Reduction In The Tumor Absorbed Radiation Dose 9/6/2016
Sangamo (SGMO) Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing 9/6/2016
Achillion (ACHN) Presents Novel Research On Factor D Inhibition At The XXVIth International Complement Workshop 9/6/2016
Opko Health (OPK) To Present Long-Acting Human Growth Hormone (HGH-CTP) Phase II Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Pediatric Endocrinology 9/6/2016
Oncotelic And Autotelic Announce Clinical Data Supporting IL-8 Spike As A Prognostic Biomarker For Immunotherapy 9/2/2016
Viking Therapeutics (VKTX) Presents Phase 1 Data And Highlights Ongoing Phase 2 Study Of VK5211 At 5th Fragility Fracture Network Global Congress 2016 9/1/2016
NovoCure Release: International Journal Of Cancer Publishes Data Showing Tumor Treating Fields In Combination With Paclitaxel Is Therapeutically Effective Against Ovarian Cancer Cells In Vitro And In Vivo 9/1/2016
Cascadian Therapeutics (ONTY) Announces Approval Of Nonproprietary Name “Tucatinib” For Lead Product Candidate ONT-380 9/1/2016
OncoMed (OMED) Completes Enrollment Of Phase II YOSEMITE Clinical Trial Of Demcizumab In Pancreatic Cancer 9/1/2016
Sensorion Obtains FDA Approval To Initiate A Clinical Study Of SENS-111 In Acute Severe Vertigo 9/1/2016
Key Parkinson's Trial Delayed Due to Feud Between a Georgetown University Scientist and The Michael J. Fox Foundation 8/31/2016
Primex Pharma: Next Real Innovation In Paediatric Anaesthesia Since Propofol 8/31/2016
The Medicines Company (MDCO) Losing Ground on News That Interim Data for Plaque Buster Med is Inconclusive 8/31/2016
Heart Metabolics Limited Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy 8/31/2016
Asterias Biotherapeutics Receives Safety Clearance To Begin Administering The Highest Dose Of AST-OPC1 In The SCiStar Phase 1/2a Clinical Trial In Cervical Spinal Cord Injury Patients 8/31/2016
Karyopharm (KPTI) To Host Conference Call With Update On Multiple Myeloma Plans 8/31/2016
Array BioPharma (ARRY) Presents Data From Cardiovascular Trial With ARRY-797 At The European Society of Cardiology Congress 8/30/2016
Kamada Ltd. (KMDA) Meets Primary Endpoint Of U.S. Phase II Study Of Inhaled Alpha-1 Antitrypsin For The Treatment Of Alpha-1 Antitrypsin Deficiency 8/30/2016
Oragenics (OGEN) Receives Supportive FDA Feedback For Initiating A Phase II Study Protocol For Oral Mucositis Treatment 8/30/2016
OncoMed (OMED) Completes Enrollment Of Phase II PINNACLE Clinical Trial Of Tarextumab In Small Cell Lung Cancer 8/30/2016
Betagenon AB: Start Of Phase IIa Proof-Of-Concept Clinical Trial Of AMPK Activator O304 In Type 2 Diabetics 8/30/2016
Alexion (ALXN) Release: European Commission (EC) Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD) 8/30/2016
Bone Therapeutics Announces H1 Results For 2016 8/30/2016
CardioCell Reports Positive Results From The First Phase Ila Clinical Trial Using IV Administration Of Stem Cells For Chronic Heart Failure Indications 8/29/2016
Shionogi Presents Results From A Phase 2 Proof-Of-Concept Clinical Trial And Non-Clinical Studies Of S-033188, A Novel Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza 8/29/2016
European Society of Cardiology Congress 2016 Late Breaking Science Registry: Latest Data On Pradaxa (Dabigatran Etexilate Mesylate) Safety And Effectiveness Profile Show Low Rates Of Bleeding And Stroke In NVAF Patients In Routine Clinical Care 8/29/2016
Tonix Pharma (TNXP) Announces Successful End-Of-Phase II Meeting With FDA For TNX-102 SL In Post-Traumatic Stress Disorder 8/29/2016
Seqirus Presents Analysis Reinforcing The Safety And Immunogenicity Profiles Of Its MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine In Adults 65 Years And Older 8/29/2016
Cerecor Inc. Announces Initiation Of Second CERC-501 Phase II Clinical Trial In Smokers 8/29/2016
Kadmon Initiates Phase II Clinical Trial Evaluating Tesevatinib In Glioblastoma 8/29/2016
NLS Pharma Announces Start Of Its Phase 2 Trial For Mazindol In Adult ADHD Patients 8/29/2016
Abeona Therapeutics Completes Enrollment Of Low-Dose Cohort For ABO-102 In Phase 1/2 Clinical Trial For MPS IIIA Patients 8/29/2016
ERYtech Pharma Completes Patient Enrollment In Phase IIb Trial For Eryaspase (GRASPA) In Acute Myeloid Leukemia 8/29/2016
Exalenz Bioscience Announces Collaboration With Conatus Pharma To Use BreathID To Monitor Patients With Cirrhosis Associated With NASH 8/29/2016
Heron (HRTX) Announces Poster Presentations Of Data From Phase II Clinical Program For HTX-011 At PAINweek 2016 8/29/2016
Biotie: BTT1023 Receives Orphan Drug Designation In The United States 8/26/2016
Biophytis: Enrollment Of The First Subjects In The Pharmacokinetics Study On Sarcopenia 8/26/2016
SCYNEXIS, Inc. (SCYX) Receives Orphan Drug Designation For SCY-078 For The Treatment Of Invasive Aspergillus Infections 8/25/2016
Themis: Phase 2 Trial Of Leading Chikungunya Vaccine Candidate Started 8/25/2016
iX Biopharma Makes Significant Strides In Drug Development In FY16 8/25/2016
Highland Therapeutics Announces Initiation Of Phase II Trial For HLD100 In Pediatric ADHD Patients 8/25/2016
BioPharmX Enrolls First Subject In Opal Phase 2b Clinical Trial Of Bpx-01 Topical Minocycline For The Treatment Of Acne 8/24/2016
Vaccinex, Inc. Receives Orphan Drug Designation From U.S. FDA For Its Lead Antibody Product Candidate, VX15, As A Potential Treatment For Huntington’s Disease 8/24/2016
Why Eli Lilly (LLY) Execs are Bullish About Its Alzheimer's Drug Solanezumab 8/23/2016
Struggling Tokai Pharma (TKAI) Nixes Enrollment in Mid-Stage Prostate Cancer Study 8/23/2016
CytoDyn (CYDY) Release: Patients Approach Two Years Of Complete HIV Viral Load Suppression In Phase IIb PRO 140 Monotherapy Extension Study 8/23/2016
ImmunoPhotonics Announces First Patient Dosed In A Randomized, Controlled Breast Cancer Clinical Trial For Incvax – A Novel Investigational Immuno-Oncology Therapy 8/23/2016
Lycera Announces Initiation Of Phase 2 Clinical Trial Of LYC-30937-EC In Patients With Ulcerative Colitis 8/22/2016
BioPharmX Announces Final Phase 2a Trial Results Find BPX-01 Reduces Facial P. Acnes By More Than 90% In Four Weeks 8/22/2016
A Look at Amgen (AMGN)'s Pipeline: Will it Help the Company Grow? 8/19/2016
Xenetic Biosciences Announces FDA Acceptance Of Investigational New Drug Application To Initiate Phase II Clinical Trial Of Virexxa In Endometrial Cancer 8/19/2016
Cerulean (CERU) Shares Decimated as Renal Cell Carcinoma Drug Comes Up Short in Mid-Stage Study 8/18/2016
Aclaris (ACRS) Announces Positive Results In Phase II Clinical Trial Of A-101 For Treatment Of Common Warts 8/18/2016
Cerulean (CERU) Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin Combination In Relapsed Renal Cell Carcinoma 8/18/2016
Boston's Juniper Pharma (JNP) Terminates Development of Lidocaine Bioadhesive Gel After Phase II Trial Failure 8/18/2016
ARCA biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial 8/18/2016
INSYS Announces First Patient Enrolled In Phase II Trial For The Treatment Of Cocaine Dependence Using Pharmaceutical Cannabidiol 8/18/2016
Nordic Nanovector Completes Recruitment Of The First Cohorts Of Arm 3 And Arm 4 Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients 8/18/2016
Inspyr (GNSZ) Announces The Initiation Of A Phase 2 Clinical Trial Of Mipsagargin For Newly Diagnosed Prostate Cancer Patients 8/17/2016
Oncoceutics Awarded FDA Orphan Grant For ONC201 Multiple Myeloma Trial 8/17/2016
Ark Biosciences Of Shanghai Starts Phase II Trial Of Novel RSV Treatment 8/17/2016
Janssen R&D Release: Esketamine Receives Breakthrough Therapy Designation from FDA for Major Depressive Disorder with Imminent Risk for Suicide 8/16/2016
Three CardioCell-Sponsored Studies Reveal Results At The European Society of Cardiology Congress 2016 8/16/2016
CASI Pharma (CASI) Met Endpoint in Phase II ENMD-2076 in Fibrolamellar Carcinoma 8/16/2016
vTv Therapeutics (VTVT) Completes Enrollment Of Phase 2 Trial Evaluating TTP273 For The Treatment Of Type 2 Diabetes 8/16/2016
Millendo Therapeutics Announces Initiation Of Phase 2b Clinical Trial Of MLE4901 In Patients With Polycystic Ovary Syndrome 8/16/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
Bristol-Myers Squibb (BMY) Investors: Wait on Opdivo Data to See Potential in Lung Cancer 8/15/2016
Aurinia (ISA.TO)'s Voclosporin Meets Primary Endpoint in Phase IIB Aura-LV Study in Lupus Nephritis 8/15/2016
ProNAi Therapeutics Shuts Down Research Site for Failed Cancer Candidate PNT2258 8/15/2016
NovaDigm Therapeutics Announces Positive Results From First-Ever Antifungal Immunotherapy In A Phase 2a Study In Women With Recurrent Vulvovaginal Candidiasis (RVVC) 8/15/2016
AVEO Oncology (AVEO) Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) In Advanced Renal Cell Carcinoma 8/15/2016
MMJ PhytoTech Ltd To Commence Phase 2 Clinical Trial On Pediatric Epilepsy 8/15/2016
Neurotrope Submits An Amended Protocol To The FDA For Its Phase 2b Clinical Trial Of Its Lead Drug Candidate, Bryostatin-1, For The Treatment Of Advanced Alzheimer's Disease 8/15/2016
Tonix Pharma (TNXP) Presents Poster On The Development Of TNX-102 SL For Post-Traumatic Stress Disorder (PTSD) At The 2016 Military Health System Research Symposium 8/15/2016
ProMetic Life Sci (PFSCF.PK) Completes Patients' Enrolment In Pivotal Plasminogen Phase 2/3 Clinical Trial 8/11/2016
Advaxis (ADXS) Announces That Phase II Head And Neck Cancer Study With AXAL Advances To Second Stage 8/11/2016
CryoPort Expands Agreement With Stemedica Cell Technologies, Inc. To Support A Phase II Clinical Trial To Assess A Stem Cell Therapy For The Treatment Of Alzheimer's Disease 8/11/2016
Achillion (ACHN) Announces Upcoming Presentation Of Interim Phase IIa Results From The Janssen Pharmaceutical Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference 8/11/2016
Medivir (MVRBF): New Interim Phase IIa Data On Simeprevir In Combination With Other Daas Will Be Presented At The Upcoming EASL AASLD Special Conference 8/11/2016
12-Employee Lexington Biotech, Aldeyra (ALDX) Shows Off Positive Drug Trial Data 8/10/2016



//-->